{
    "nctId": "NCT03242616",
    "briefTitle": "PemVin vs Vin in Previously Treated Metastatic Breast Cancer",
    "officialTitle": "Randomized Phase II Trial of Pemetrexed Plus Vinorelbine Versus Vinorelbine in Patients With Recurrent or Metastatic Breast Cancer Previously Treated With or Resistant to Anthracycline and Taxane",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 125,
    "primaryOutcomeMeasure": "progression free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. histologically confirmed, recurrent or metastatic breast cancer\n2. HER2-negative\n3. ECOG PS 0-2\n4. Age \u2265 20 years\n5. Anthracycline- and Taxane-pretreated\n6. Wash-out period of 3 weeks for cytotoxic chemotherapy\n7. Wash-out period of 2 weeks for hormone therapy or radiotherapy\n8. measurable or non-measurable lesions by RECIST v1.1\n9. Adequate hematological functions : ANC \u22651,500/mm3, Platelet \u2265100,000/mm3, Hb\u2265 9g/dL\n10. Adequate liver functions\n11. Adequate renal functions : sCr\u22641.5mg/dL\n12. Subjects willing to follow study protocol\n13. Informed consent before study entry\n\nExclusion Criteria:\n\n1. More than 3 lines of chemotherapy for metastatic breast cancer\n2. Pregnant or breastfeeding women\n3. Previous exposure to Pemetrexed or Vinorelbine\n4. Neuropathy (grade 2 or more)\n5. Symptomatic CNS metastasis\n6. History of malignant disease within 5 years (except for cured basal cell cancer or squamous cell cancer of skin, cured thyroid cancer, in-situ cervical cancer)\n7. Hypersensitivity to study medication or related drugs\n8. Concomitant vaccination for yellow fever",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}